The pulse is the message

Most of the endocrine system speaks in amounts. A gland releases more or less of a hormone, a receptor reads the concentration, the response scales. The reproductive axis is the great exception. Its master signal, GnRH, carries its meaning not in how much arrives but in how often. The hypothalamus releases GnRH in discrete pulses, roughly one an hour in the reproductive state, and the pituitary below it decodes the beat.

The axis is a three-storey cascade. GnRH from the hypothalamus drives the pituitary to release two gonadotropins, LH and FSH; those travel to the gonads to make sex steroids and gametes; the steroids feed back to set the tempo. Everything about it (puberty, the menstrual cycle, fertility, and every drug that suppresses or restores them) turns on one counterintuitive rule: the pulse is the message. Read the rhythm, and the whole family, its strangest pharmacology included, falls into place.

The proof is one of the cleanest experiments in endocrinology. In the late 1970s, Ernst Knobil’s group worked with monkeys whose own GnRH neurons had been destroyed, leaving the pituitary intact but silent. Infused with GnRH in hourly pulses, the animals’ LH and FSH returned to normal and the axis switched back on. Infused with the exact same GnRH continuously, at the same total dose, their gonadotropins collapsed (Belchetz and Knobil, Science, 1978). Same molecule, same amount, opposite outcome. The only variable was rhythm.

The mechanism is receptor desensitization. A GnRH receptor that is pulsed recovers between beats and answers each one; a receptor bathed continuously downregulates, uncouples from its signaling, and goes quiet. Later work mapped how the beat itself is decoded downstream, with faster pulses biasing the pituitary toward LH and slower ones toward FSH, so the axis tunes its two outputs by frequency alone (Stamatiades et al., 2018). The pituitary is not a volume meter. It is a frequency decoder.

Here the pharmacology gets strange, and rather beautiful. If continuous GnRH shuts the axis down, then a drug that mimics GnRH but never stops should be a suppressant, not a stimulant. That is exactly what a GnRH agonist is. Leuprolide and goserelin are engineered GnRH analogs, more potent and longer-lasting than the native decapeptide, delivered as depots that hold a continuous high level for months. For the first days they genuinely stimulate: the flare, a surge of LH and sex steroids. Then the receptor desensitizes and the axis goes dark.

A super-agonist used to switch a system off is a genuine oddity, and it is one of the most-used tricks in medicine. Continuous GnRH-agonist suppression is how prostate cancer is deprived of testosterone, how endometriosis and fibroids are starved of estrogen, how central precocious puberty is paused, and how an IVF cycle is downregulated before controlled stimulation. The flare is the catch: in advanced prostate cancer that first testosterone surge can briefly worsen the disease, which is why it is managed with care. The drug works by overwhelming the code the axis depends on. It shouts the ON signal so loudly, and so constantly, that the receptor stops listening.

If the agonist reaches OFF by the scenic route (stimulate, flare, then desensitize), the antagonists take the direct one. Cetrorelix, ganirelix, degarelix and relugolix bind the GnRH receptor and block it, so gonadotropin release falls immediately, with no flare. The clinical value is precisely the absence of the surge: in IVF an antagonist prevents a premature LH surge without the downregulation lead-in, and in prostate cancer it drops testosterone without the initial spike.

For decades that clean suppression still cost a needle, because the antagonists were peptides. The recent shift is that one of them is not. Relugolix is a small-molecule GnRH antagonist taken as a daily pill, and in a head-to-head trial against the agonist leuprolide it suppressed testosterone faster and was associated with fewer of the major cardiovascular events that shadow androgen deprivation (Shore et al., NEJM, 2020). It is the same move the incretin field is making with oral GLP-1: a receptor reads the message, not the messenger, so the messenger can stop being a peptide.

For all its elegance, the pulse generator raised a harder question: what sets the beat? The answer arrived through a genetics puzzle. Families whose children never entered puberty, and who had low gonadotropins for no structural reason, turned out to share loss-of-function mutations in a receptor then called GPR54 (de Roux et al., PNAS, 2003). Its ligand is kisspeptin, a hypothalamic peptide acting one storey above GnRH. Knock out its receptor and the GnRH pulse never starts; the axis is fully built, but never switched on.

The mirror sealed it. A child carrying an activating mutation in the same receptor entered puberty extraordinarily early (Teles et al., NEJM, 2008). Too little kisspeptin signaling and puberty fails to begin; too much and it begins too soon. Kisspeptin neurons sit at the hypothalamic KNDy hub and integrate the inputs that gate reproduction: sex-steroid feedback, and the metabolic signals that explain why energy balance and body fat move the reproductive axis at all. The pulse everyone had studied since Knobil had a gatekeeper, and it had been hiding in a broken gene.

Kisspeptin also pointed toward a gentler kind of drug. The problem with triggering ovulation in IVF is the trigger itself: the standard hCG bolus is a powerful, long-lasting LH-like jolt that can tip high responders into ovarian hyperstimulation syndrome. Kisspeptin does something the axis recognizes as physiological. It asks the hypothalamus to release its own GnRH, producing a self-limiting LH surge rather than an imposed one. In trials, a single dose of kisspeptin-54 matured eggs effectively (Jayasena et al., 2014), and in women at high risk of hyperstimulation it did so with a markedly safer profile (Abbara et al., 2015).

That is the whole thesis turned into a strategy. The agonists and the hCG trigger overwhelm the system with a signal it cannot ignore; kisspeptin nudges the gate and lets the axis produce its own pulse. Working with the rhythm rather than against it is the newer, quieter frontier, and it runs the length of the family: pulsatile GnRH pumps that restore fertility by supplying the missing beat, antagonists that block without the surge, kisspeptin that triggers by asking rather than forcing.

Step back and the reproductive axis is the clearest case in physiology of a signal that lives in time rather than in concentration. Its hormones are famous (testosterone, estrogen, the LH surge of ovulation), but the control layer above them is a rhythm, and almost every drug in the family is a way of writing to that rhythm or jamming it. Read the pulse and the paradoxes resolve: why a stimulant suppresses, why an antagonist is kinder than an agonist, why puberty waits on a single gene, and why the gentlest fertility trigger is the one that asks the hypothalamus to speak for itself.

• The signal is the rhythm, not the level. GnRH is pulsatile, and the pituitary decodes frequency. Knobil's monkeys proved it: pulsed GnRH switches the axis on, the same GnRH given continuously switches it off.
• The agonist paradox. Leuprolide and goserelin stimulate so constantly that the receptor desensitizes. After an initial flare they suppress the axis. A super-agonist used, deliberately, as an off switch.
• Antagonists are the clean mirror. Cetrorelix and relugolix block the receptor for immediate, flare-free suppression. Relugolix is oral and beat injected leuprolide head-to-head, the small-molecule move the GLP-1 field is also making.
• Kisspeptin is the gate. It sets the pulse one storey above GnRH. Genetics revealed it: lose the receptor and puberty never starts, over-activate it and puberty comes early.
• The frontier works with the rhythm. Kisspeptin triggers ovulation by asking the hypothalamus for its own surge, maturing eggs with far less hyperstimulation risk than an hCG bolus. Speak the axis's language instead of shouting over it.